Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Nilvadipine in hypertension with renal dysfunction.

H H Berger1, F W Albert

  • 1Medizinische Klinik III, Klinikum Kaiserslautern, Germany.

Journal of Cardiovascular Pharmacology
|January 1, 1992
PubMed
Summary

Nilvadipine effectively lowers blood pressure in patients with hypertension, regardless of renal function. An 8 mg daily dose of this calcium channel blocker is safe and well-tolerated in individuals with mild to moderate kidney impairment.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Interleukin-2 determinations for monitoring the renal allograft.

Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association·2013
Same author

Targeted resequencing of a genomic region influencing tameness and aggression reveals multiple signals of positive selection.

Heredity·2011
Same author

A locus for an auditory processing deficit and language impairment in an extended pedigree maps to 12p13.31-q14.3.

Genes, brain, and behavior·2010
Same author

Contrast-enhanced ultrasound for the characterization of focal liver lesions--diagnostic accuracy in clinical practice (DEGUM multicenter trial).

Ultraschall in der Medizin (Stuttgart, Germany : 1980)·2009
Same author

[Haemostatic testing prior to elective surgery? Yes!].

Hamostaseologie·2009
Same author

Fibrinogen kaiserslautern III: a new case of congenital dysfibrinogenemia with aalpha 16 arg-->cys substitution.

Haemostasis·2001

Area of Science:

  • Pharmacology
  • Nephrology
  • Cardiology

Background:

  • Dihydropyridine calcium antagonists are used to treat hypertension.
  • Renal function can influence drug pharmacokinetics and pharmacodynamics.
  • Nilvadipine is a novel dihydropyridine calcium antagonist.

Purpose of the Study:

  • To evaluate the pharmacokinetics and pharmacodynamics of nilvadipine in hypertensive patients with varying degrees of renal function.
  • To determine the safety and efficacy of a single daily dose of 8 mg nilvadipine.

Main Methods:

  • 16 patients with arterial hypertension were divided into two groups based on renal function (creatinine clearance 15-50 ml/min vs. >80 ml/min).
  • Patients received 8 mg nilvadipine once daily for 10 days after a placebo washout period.

Related Experiment Videos

  • Pharmacokinetic parameters, blood pressure, heart rate, and relevant biochemical markers were monitored.

    • Main Results:

    • Nilvadipine significantly reduced diastolic blood pressure in both groups compared to placebo.
    • No significant changes in heart rate, renin, aldosterone, or electrolytes were observed.
    • Pharmacokinetics of unchanged nilvadipine did not differ significantly between groups; metabolite excretion varied slightly in patients with impaired renal function.

    Conclusions:

    • Single daily doses of 8 mg nilvadipine are effective and well-tolerated in hypertensive patients.
    • The study does not indicate a need for dose reduction in patients with creatinine clearance between 15-50 ml/min.
    • Nilvadipine demonstrates a favorable profile in managing hypertension with limited renal function.